China Resources Shuanghe announced that the company recently received the “Drug Registration Certificate” for compound glucose/electrolyte brain surgery rinse issued by the State Drug Administration. The drug is a type 3 chemical rinse agent and is suitable for neurosurgical scenarios such as skull drilling and craniotomy cleaning. This approval is considered to have passed the consistency evaluation, and the production line must pass a GMP compliance check before it can be marketed. As of the announcement date, the company has invested a total of 13.2462 million yuan in research and development of this drug. The approval of the drug will enrich the company's product line, and there is uncertainty about its sales situation due to policy, market and other factors.

China Resources Shuanghe announced that the company recently received the “Drug Registration Certificate” for compound glucose/electrolyte brain surgery rinse issued by the State Drug Administration. The drug is a type 3 chemical rinse agent and is suitable for neurosurgical scenarios such as skull drilling and craniotomy cleaning. This approval is considered to have passed the consistency evaluation, and the production line must pass a GMP compliance check before it can be marketed. As of the announcement date, the company has invested a total of 13.2462 million yuan in research and development of this drug. The approval of the drug will enrich the company's product line, and there is uncertainty about its sales situation due to policy, market and other factors.